Over the course of nearly five decades, Biogen has played a major role in catalyzing and shaping Kendall Square in Cambridge, Massachusetts, now heralded as the “most innovative square mile on the planet.” Today, Biogen announced its decision to centralize operations in a new facility at 75 Broadway in MIT’s Kendall Common development. The move, which will take place in 2028, highlights the company’s commitment to Cambridge and the regional innovation ecosystem — a wellspring of biomedical advances.
“It’s fitting that Biogen — a company with such close ties to people at MIT — will make Kendall Common’s first building its new home,” says MIT President Sally Kornbluth. “The motto of Kendall Square might as well be ‘talent in proximity’ and Biogen’s decision to intensify its presence here promises great things for the whole ecosystem. To achieve this milestone on the occasion of the company’s 50th anniversary is especially meaningful. We are grateful to Chris Viehbacher, president and chief executive officer of Biogen, for his keen vision of the future and his ongoing commitment to Cambridge and Kendall Square.”
The approximately 580,000-square-foot facility will integrate Biogen’s research and development teams together with its global and North American commercialization organizations. The building will incorporate advanced conservation, efficiency, and sustainable design elements.
“Biogen’s story in Kendall Square is unlike any other,” says Anantha Chandrakasan, MIT’s chief innovation and strategy officer. “Institute Professor Phil Sharp’s early work in genetics and molecular biology and his co-founding of Biogen in 1978 set life sciences on a bold trajectory in the region — and in the world. MIT’s intertwined history with Biogen has benefited society through significant research advancements — from classroom and lab to market — in treating multiple sclerosis, Parkinson’s disease, and other neuromuscular disorders. I’m so pleased that our fruitful partnership will continue.”
The new building, designed by Elkus-Manfredi Architects, will activate the corner at 75 Broadway, and protect and accentuate the abutting 6th Street Walkway — a favorite tree-lined path for residents and Kendall employees alike. A joint venture partnership between the MIT Investment Management Company and BioMed Realty, a Blackstone Real Estate portfolio company, is facilitating advancement of the project.
“Helping to ensure that Biogen stays in Cambridge was very important to us,” says Patrick Rowe, senior vice president in MIT’s real estate group, which is part of the Institute’s investment management company. “The company’s nearly 50-year history is a foundational component of the Kendall Square innovation ecosystem.”
“We are thrilled to partner with MIT in the development and activation of this world-class lab and office asset in the heart of Kendall Square,” says Bill Kane, BioMed Realty’s president of East Coast and U.K. markets. “75 Broadway will provide mission-critical infrastructure to Biogen that enables the development of the next generation of life-saving medicines and therapies.”
Ultimately, the 10-acre Kendall Common development will include eight buildings for residential, office, lab, retail, and community uses. The project’s 10-year review process and federal agreement led to the recent opening of the MIT-built John A. Volpe National Transportation Systems Center.
